Cargando…
New Surgical Circulatory Support System Outcomes
We report the first U.S. experience of the recently approved micro-axial surgical heart pump for the treatment of ongoing cardiogenic shock following acute myocardial infarction (AMICGS), postcardiotomy cardiogenic shock (PCCS), cardiomyopathy including myocarditis, high-risk percutaneous coronary i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316144/ https://www.ncbi.nlm.nih.gov/pubmed/32541335 http://dx.doi.org/10.1097/MAT.0000000000001194 |
_version_ | 1783550383278260224 |
---|---|
author | Ramzy, Danny Soltesz, Edward Anderson, Mark |
author_facet | Ramzy, Danny Soltesz, Edward Anderson, Mark |
author_sort | Ramzy, Danny |
collection | PubMed |
description | We report the first U.S. experience of the recently approved micro-axial surgical heart pump for the treatment of ongoing cardiogenic shock following acute myocardial infarction (AMICGS), postcardiotomy cardiogenic shock (PCCS), cardiomyopathy including myocarditis, high-risk percutaneous coronary intervention (HRPCI), and coronary artery bypass surgery (HRCABG). Demographic, procedural, hemodynamic, and outcome data were obtained from the manufacturer’s quality database of all Impella 5.5 implants at three centers. Fifty-five patients underwent an Impella 5.5 implant for cardiomyopathy (45%), AMICGS (29%), PCCS (13%), preop CABG (5%), OPCAB (4%), and other (4%). Thirty-five patients (63.6%) were successfully weaned off device with recovery of native heart function. Eleven patients (20.0%) were bridged to another therapy, two patients (3.6%) expired while on support, and in seven patients (12.7%) care was withdrawn. Overall survival was 83.6%. There were no device-related strokes, hemolysis, or limb ischemia observed. Four patients experienced purge sidearm damage, resulting in a pump stop in two patients. The new micro-axial surgical heart pump demonstrated successful clinical and device performance in providing both full hemodynamic support and ventricular unloading for patients with AMICGS, decompensated cardiomyopathy, and high-risk cardiac procedures. In this early U.S. experience, 83.6% of patients survived to explant with 76.1% of these patients recovering native heart function. |
format | Online Article Text |
id | pubmed-7316144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-73161442020-07-09 New Surgical Circulatory Support System Outcomes Ramzy, Danny Soltesz, Edward Anderson, Mark ASAIO J Adult Circulatory Support We report the first U.S. experience of the recently approved micro-axial surgical heart pump for the treatment of ongoing cardiogenic shock following acute myocardial infarction (AMICGS), postcardiotomy cardiogenic shock (PCCS), cardiomyopathy including myocarditis, high-risk percutaneous coronary intervention (HRPCI), and coronary artery bypass surgery (HRCABG). Demographic, procedural, hemodynamic, and outcome data were obtained from the manufacturer’s quality database of all Impella 5.5 implants at three centers. Fifty-five patients underwent an Impella 5.5 implant for cardiomyopathy (45%), AMICGS (29%), PCCS (13%), preop CABG (5%), OPCAB (4%), and other (4%). Thirty-five patients (63.6%) were successfully weaned off device with recovery of native heart function. Eleven patients (20.0%) were bridged to another therapy, two patients (3.6%) expired while on support, and in seven patients (12.7%) care was withdrawn. Overall survival was 83.6%. There were no device-related strokes, hemolysis, or limb ischemia observed. Four patients experienced purge sidearm damage, resulting in a pump stop in two patients. The new micro-axial surgical heart pump demonstrated successful clinical and device performance in providing both full hemodynamic support and ventricular unloading for patients with AMICGS, decompensated cardiomyopathy, and high-risk cardiac procedures. In this early U.S. experience, 83.6% of patients survived to explant with 76.1% of these patients recovering native heart function. Lippincott Williams & Wilkins 2020-06-10 2020-07 /pmc/articles/PMC7316144/ /pubmed/32541335 http://dx.doi.org/10.1097/MAT.0000000000001194 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASAIO. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Adult Circulatory Support Ramzy, Danny Soltesz, Edward Anderson, Mark New Surgical Circulatory Support System Outcomes |
title | New Surgical Circulatory Support System Outcomes |
title_full | New Surgical Circulatory Support System Outcomes |
title_fullStr | New Surgical Circulatory Support System Outcomes |
title_full_unstemmed | New Surgical Circulatory Support System Outcomes |
title_short | New Surgical Circulatory Support System Outcomes |
title_sort | new surgical circulatory support system outcomes |
topic | Adult Circulatory Support |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316144/ https://www.ncbi.nlm.nih.gov/pubmed/32541335 http://dx.doi.org/10.1097/MAT.0000000000001194 |
work_keys_str_mv | AT ramzydanny newsurgicalcirculatorysupportsystemoutcomes AT solteszedward newsurgicalcirculatorysupportsystemoutcomes AT andersonmark newsurgicalcirculatorysupportsystemoutcomes |